Pfizer to broaden RSV portfolio with deal to acquire ReViral for up to $525 million

  • In a bid a strengthen its portfolio targeted at respiratory syncytial virus (RSV), Pfizer (NYSE:PFE) has agreed to acquire privately-held ReViral for a total consideration of up to $525 million, including upfront and development milestones.
  • ReViral has clinical candidates targeted at RSV infection, including sisunatovir, an oral inhibitor to block viral fusion to host cells.
  • Backed by Fast Track designation by the U.S. Food and Drug Administration (FDA), sisunatovir is currently undergoing Phase 2 studies in infants following a phase 2 RSV human challenge study in healthy adults.
  • The programs, being advanced by ReViral, are expected to generate more than $1.5 billion of annual revenue if successful, according to Pfizer (PFE).
  • 'The proposed acquisition of ReViral's pipeline of therapeutic candidates is complementary to our efforts to advance the first vaccine candidate to help protect against this harmful disease," said Annaliesa Anderson, a Senior Vice President at the company.

    For this year the company, located in New York City revenue will be around 105.44 billion USD. This is according to the average of the analysts' estimates. The expected revenue would be a record for the company. This is rather significant more than 2021's revenue of 81.29 billion USD.

    Historical revenues and results Pfizer plus estimates 2022

    aandelenanalyse

    The analysts expect for 2022 a net profit of 39.47 billion USD. For this year the consensus of the result per share is a profit of 6.86 USD. So the price/earnings-ratio equals 7.24.

    Huge dividend Pfizer

    Per share the analysts anticipate on a dividend of 1.65 USD per share. The dividend yield is then 3.32 percent. The average dividend yield of the pharmaceutical companies is a limited 1.37 percent.

    Most recent target prices around 53 USD

    The most recent recommendations for the pharmaceutical company are from JP Morgan, Barclays and UBS .

    Pfizer 's market capitalization is around 276.46 billion USD. 29

    On Wednesday the stock closed at 49.66 USD.

    Historical stock prices Pfizer

    stock analysis pfizer

    ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
    news@valuespectrum.com

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.